News
Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections.
Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.
The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce’s efforts to combat antimicrobial resistance.
The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts’ Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.
Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce’s anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
ASX health stocks today: AdAlta (ASX:1AD) leads after successful Phase I study
Health & Biotech
ScoPo’s Powerplays: ASX biotech IPOs show ‘money is out there’; Virtus to benefit from rise in IVF
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Recce, Botanix both announce progress on antimicrobial programs
News
Market highlights and 5 ASX small caps to watch on Tuesday
News
Last Orders: ASX finishes firmly in the red led by tech
Health & Biotech
Chimeric IPO: What ASX stockspert Bhavdip143 likes so much about the $35m CAR T play
Health & Biotech
Superbugs will kill 22,000 Australians annually by 2040; but these stocks are trying to stop that
News
Rise and Shine: What you need to know before the ASX opens
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Check up: dorsaVi leads ASX health gainers with 60pc rise
Experts
ScoPo’s Health Powerplays: The money keeps flowing for the ASX biotechs
Health & Biotech
This new antimicrobial resistance network could boost Recce, Botanix and Next Science
News
Rise and Shine: What you need to know before the ASX opens
News
Rise and Shine: What you need to know before the ASX opens
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech